Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined photocoagulation and photodynamic therapy

a combination of applied in the field of combined photocoagulation and photodynamic therapy, can solve the problems of photocoagulation of an entire cnv, affecting the treatment effect, so as to increase the concentration of pdt agent in the lesion, the effect of effective treatmen

Inactive Publication Date: 2008-09-11
NOVADAG TECH INC
View PDF25 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]One advantage of the present invention is that by cutting off the blood flow using photocoagulation or DEP after administration of the PDT agent, the PDT agent becomes incarcerated in the lesion. This is significant as PDT agents, such as Visudyne™, were previously thought to be held in the lesion during treatment because they were selectively bound to lesion tissues. However, it has come to light that PDT agents may not be as selectively bound to lesion tissues, such as CNVs, as originally anticipated. Therefore, by cutting off the blood flow to the lesion, once it has become at least partially filled with PDT agent, the PDT agent is physically held in the lesion for and during PDT.
[0017]A further advantage is that the incarceration of the PDT agent in the lesion also allows the PDT agent in non-lesion areas to be flushed out at higher flush-out rates as compared to lesion areas. As a result, non-lesion areas will be subjected to less PDT mediated damage while maintaining PDT agent in the lesion area.
[0018]A still further advantage is that the incarceration of PDT agent m the lesion increases the concentration of PDT agent in the lesion during treatment. A higher concentration of PDT agent in the lesion allows for more effective treatment.
[0019]A still further advantage is that given that the PDT agent can be effectively concentrated in the lesion, the overall amounts of PDT agent used can be lowered. In the instance where PDT agent is infused, infusion time can therefore be correspondingly lowered. This is economically advantageous and decreases the likelihood of side effects resulting from the PDT agent.
[0020]A still further advantage is that the reduction of blood flow through the feeder vessel enhances the rate of PDT-induced clot formation during PDT by reducing the movement and flow of blood through the lesion.
[0021]A still further advantage is that, in the case of AMD-related CNV, post-PDT sensitivity to sunlight is significantly greatly reduced because of greatly reduced quantities of administered PDT agent.

Problems solved by technology

Photocoagulation of an entire CNV, however, involved the destruction of a significant portion of the retina.
When the agent is excited, it produces oxygen radicals which then attack the cells of the surrounding tissue, resulting in degradation of those cells.
Moreover, it now appears that the extent to which many PDT agents are selective for abnormal vasculature may not be as high as originally expected.
As a result, the non-target areas of the fundus may be subjected to more PDT-mediated damage than originally anticipated.
Large quantities of PDT agent also translate into an increase in the likelihood of side effects, higher total cost and more light sensitivity post-treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined photocoagulation and photodynamic therapy
  • Combined photocoagulation and photodynamic therapy
  • Combined photocoagulation and photodynamic therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024]In the following description, numerous specific details are set forth to provide a thorough understanding of the invention. However, it is understood that the invention may be practiced without these specific details. In other instances, well-known processes have not been described or shown in detail in order not to obscure the invention.

[0025]The methods of the present invention are claimed and described herein as a series of treatment steps. It should be understood that these methods and associated steps may be performed in any logical order that preserves the spirit of the invention. Moreover, the methods may be performed alone, or in conjunction with other procedures and treatments administered before, during or after such methods and steps set forth herein without departing from the scope and spirit of the invention. Further, it is contemplated that the term animals as used herein includes, but is not limited to, humans.

[0026]Achieving even more effective treatment of les...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for treating a lesion of an animal, the animal having at least one vessel that carries blood to the lesion, comprising locating the vessel, administering a composition comprising a photodynamic agent, applying energy to the vessel to photocoagulate the vessel and thereby reduce the rate at which the treatment composition exits said lesion and applying energy to said lesion, of a type and an amount sufficient to excite the photodynamic agent, causing the lesion to undergo photodynamic therapy. Preferably, a dye that is both a fluorescent dye and a radiation absorbing dye, such as indocyanine green dye, is added to the treatment composition to allow (a) confirmation of the presence of the treatment composition b the lesion to be detected by fluorescent angiography and (b) the rate of blow flow to be reduced in the blood vessel feeding the lesion using dye enhanced photocoagulation.

Description

[0001]This application claims priority from U.S. patent application Ser. No. 60 / 396146, filed Jul. 17, 2002.[0002]This invention relates to a method for treating lesions, and more specifically where said lesion is an age related macular degeneration associated choroidal neovascularization, wherein said neovascularization is supplied by at least one blood vessel.BACKGROUND OF THE INVENTION[0003]Lesions are normally defined as an abnormal tissue structure located in an organ or other body part, and are often a manifestation of a harmful condition, disease or illness. Lesions may take many specific forms, such as choroidal neovascularizations (“CNVs”) which are found in the eye. In general, any abnormal vasculature in a body is a type of lesion.[0004]Lesions must often be identified and visualized prior to treatment and such methods are known in the art. For example, CNVs are routinely visualized using indocyanine green (“ICG”) dye angiography (“ICGA”). It is based on use of the near-i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61B18/18A61F9/008A61N5/06
CPCA61F9/008A61N5/062A61F2009/00863A61F9/00821
Inventor FLOWER, ROBERT
Owner NOVADAG TECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products